The UK and US have concluded a major bilateral deal that will ensure zero duties on British pharmaceutical products entering the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to raise spending on drugs through the public health system. This commitment ensures that tariffs on these vital products will stay at zero for a timeframe of the next three years.
This agreement comes after recent warnings to dramatically increase duties on branded pharmaceutical imports, with increases discussed up to one hundred percent.
"This arrangement between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue balance to U.S.–U.K. medicine commerce," a statement declared.
Commercial Impact
Pharmaceuticals are one of the the United Kingdom's largest export categories to the America, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of last September, the UK sold pharmaceutical products valued at £11.1bn to the US. This figure accounted for nearly one-fifth of British export trade in that period.
"This agreement safeguards jobs, stimulates capital expenditure and facilitates the UK to emerge as a worldwide center for medical research," a government official commented.
Detailed NHS Changes
The pact entails several key changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to raise total public funding on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Previously, refunds were more than twenty percent.
Broader Context
This agreement comes amid a ongoing tension between the sector and the UK government over drug pricing and NHS adoption.
These tensions were heightened by claims that American customers were charged several times more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or cancelled, while multi-billion-dollar investments have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had decreased as a proportion of its resources over the past decade.
